EMEA Cardiac Arrest Treatment Market - 2025-2033

The EMEA cardiac arrest treatment market reached US$ 1,261.46 million in 2024 and is expected to reach US$ 2,334.68 million by 2033, growing at a CAGR of 7.3% during the forecast period 2025-2033.

Cardiac arrest occurs when the heart suddenly and unexpectedly stops pumping. If this happens, blood stops flowing to the brain and other vital organs. Cardiac arrests are caused by certain types of arrhythmias that prevent the heart from pumping blood.

The main cause of cardiac arrest is ventricular fibrillation or ventricular tachycardia, which are types of arrhythmias. Important risk factors include prior cardiac arrest, coronary heart disease, heart valve disease, congenital heart defects, and arrhythmias caused by faulty genes. However, half of cardiac arrests happen to people who did not know they had a heart problem.

Medicines called anti-arrhythmic drugs may help restore the heart rhythm. Surgeries and other treatments may also be needed to correct a heart rhythm problem, open a blockage, or place a device to help the heart work better.

Market Dynamics: Drivers & Restraints

Aging Population and Increasing Prevalence of Cardiovascular Conditions

The aging population and increasing prevalence of cardiovascular conditions are expected to drive the growth of the cardiac arrest treatment market in EMEA in the forecast period. As people age, they are more prone to developing heart-related conditions such as hypertension, coronary artery disease, and heart failure, which significantly increase the risk of cardiac arrest. The EMEA region, especially Europe, has a rapidly aging population, with a larger percentage of individuals over the age of 60.

For instance, according to the World Health Organization (WHO), the population aged 60 and older is rapidly growing in the European Union. In 2021, there were 215 million; by 2030, it is projected to be 247 million, and by 2050, over 300 million. This rising population increases the incidence cases of cardiac arrest. Elderly populations require more frequent medical interventions, including emergency treatments for cardiac events. This results in a growing need for defibrillators, implantable cardioverter defibrillators (ICDs), and drugs that can treat or prevent cardiac arrest.

Cardiovascular disease (CVD) is the leading cause of death in the EU, mainly due to heart attacks and strokes. Population aging is becoming the most important driver of the CVD epidemic. According to the European Environment Agency, every year in the EU, more than 6 million new cases of CVD are diagnosed, and over 1.7 million people die from diseases of the circulatory system.

Rising rates of obesity, poor diet, sedentary lifestyle, and smoking contribute to the increased prevalence of cardiovascular diseases across the EMEA region. These conditions are major contributors to the onset of sudden cardiac arrest (SCA). For instance, the National Institutes of Health (NIH) 2022 analysis provides estimates of the current incidence of SCD and Out-of-hospital cardiac arrest (OHCA) in Europe based on 4 large, population-based prospective registries. The findings suggest that at least 249,538 SCD and 343,496 OHCA cases are expected each year in the European Union.

According to the World Heart Federation, Cardiovascular disease is the number one cause of death in the Middle East and North Africa region, responsible for more than one-third of all deaths, or 1.4 million people every year. Deaths attributed to cardiovascular diseases range from 40% of total deaths in Oman to 10% in Somalia. Both heart attacks and strokes are significant risk factors for cardiac arrest. As these cardiovascular conditions become more widespread, especially in Europe and parts of the Middle East, the need for emergency treatment options such as AEDs and other life-saving interventions grows.

For instance, the Italian Resuscitation Council reported that the Social Affairs Commission of the chamber approved the proposed law on AEDs in Italy. The law provides for about 10 million euros (about USD 11.36 million) for implementing public access AEDs over the next five years, among other provisions.

High Cost of Cardiac Arrest Treatment

The high cost of cardiac arrest treatment and devices is expected to hamper market growth over the forecast period. In many parts of Europe, Africa, and the Middle East, the cost of cardiac arrest treatment and treatment devices such as defibrillators (AEDs), implantable cardioverter defibrillators (ICDs), and medications is prohibitively expensive for both healthcare systems and individual patients. These high costs restrict the adoption of life-saving technologies in low- and middle-income regions.

For instance, the average cost of an AED device in Europe is approximately €1,500, and the average cost of one of the major brands of AED devices i.e., Zoll AED 3 fully automatic external defibrillator, is approximately €2200.00. This higher price may limit small clinics and public facilities from purchasing this device, where it finds the majority of its use.

Additionally, according to the NIH, in 2023, in Spain, the total cost per patient with out-of-hospital cardiac arrest admitted to the hospital was €73,502, with indirect costs contributing to 54.4% of the total cost. Among direct costs, ICU and rehabilitation costs were the largest contributors, with almost 15% each of the total costs, and the targeted-temperature management (TTM) contributed 3.5% of the total costs. When analyzed by cerebral performance category (CPC) neurological outcome, the cost per patient increased as the outcome became poorer, with a cost of €28,332.7 for patients with a CPC1 score and €97,953.1 for patients with a CPC4 score.

Limited public health funding can limit the adoption of these devices in government-owned facilities, restraining access to patients who opt for care services in government hospitals. Thus, the above factors could be limiting the EMEA cardiac arrest treatment market's potential growth.

Segment Analysis

The EMEA cardiac arrest treatment market is segmented based on product type and end-user.

Product Type:

The automated external defibrillators in the product type segment are expected to dominate with the highest market share.

The emergency treatment options for cardiac arrest are given by devices such as automated external defibrillators, implantable cardioverter defibrillators (ICD), CPR devices, Intraosseous vascular access devices, cardiac resynchronization therapy (CRT) devices, and others. Automated external defibrillators are the most commonly used first-line devices to resuscitate a patient who is experiencing cardiac arrest.

An Automated external defibrillator (AED) is a medical device that is portable and is situated in hospital settings, clinics, and public places such as airports, malls, offices, government buildings, schools, police stations, etc. This device is readily accessible to the majority of patients who are having cardiac arrest. Patients with high-risk cardiovascular conditions and a higher risk of cardiac stroke will have the AED device at home as well.

AEDs can be fully automated or semi-automated. The fully automated devices analyze the heart rhythm of the patient and deliver the electric impulse without user interference. The semi-automated AED detects the heart rhythm of the patients, and if any irregularity is found, it sends a prompt to medical professionals to deliver the defibrillation shock. AED is a life-saving device in any care setting. Their simple operation, ease of use in any facility, portability, therapeutic effectiveness, and safety are the major parameters contributing to their wide adoption for cardiac arrest treatment. These factors have solidified the segment's position in the EMEA cardiac arrest treatment market.

Competitive Landscape

The major players in the EMEA cardiac arrest treatment market include Teleflex Incorporated, Medtronic, Koninklijke Philips N.V., ZOLL Medical Corporation, Stryker, SCHILLER, Dixion Distribution of Medical Devices GmbH, WEINMANN Emergency Medical Technology GmbH + Co. KG, Amiitalia, and NIHON KOHDEN CORPORATION, among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The EMEA cardiac arrest treatment market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.